Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Lilly axed other partnered programs as part of the pipeline update. The other phase 2 asset included in the latest cull, a Kv1.3 antagonist that Lilly was developing in psoriasis, originated at D ...

Eli Lilly officials and Gov. Mike Braun break ground on the LEAP District's Lilly Medicine Foundry, a $4.5 billion project creating 400 jobs.

Unlike many of its big pharma peers, Eli Lilly (LLY -1.04%) is a growth stock that's likely to maintain a faster-than-average pace of expansion over the next few years. Between its massive ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH By Nick Paul Taylor Feb 10, 2025 9:40am Eli Lilly MASH radiopharmaceuticals Licensing deals ...

Eli Lilly and Co. officially opened its new Lilly Seaport Innovation Center on Tuesday. Gary Higgins / Boston Business Journal 1 of 11 By Hannah Green – Reporter, Boston Business Journal Aug 13 ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap — but when it comes to invention, AstraZeneca, with its wealth of experimental ...

Along the corridors of Indianapolis-based Eli Lilly, NBP may not have the brand swagger of Trulicity or Mounjaro, but as the drugmaker eyes a rich menu of growth opportunities, the sturdy acronym ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology ...

Pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca got a ratings boost from Berenberg analysts from their respective returns on R&D investment, and ability to withstand ...